PMC:6537946 / 26744-28430 JSONTXT

{"project":"0_colil","denotations":[{"id":"31106338-28779893-6312","span":{"begin":472,"end":473},"obj":"28779893"},{"id":"31106338-25888086-6313","span":{"begin":825,"end":827},"obj":"25888086"},{"id":"31106338-25443013-6314","span":{"begin":1031,"end":1033},"obj":"25443013"},{"id":"31106338-20197346-6315","span":{"begin":1682,"end":1684},"obj":"20197346"}],"text":"Facing increasing donor ages, all means must be undertaken to assess donated hearts as thoroughly as possible. New preservation technology [Organ Care System® (OCS), TransMedics, Andover, MA, USA] has been introduced to reduce ischaemic damage to the graft and enable further examination. This commercially available device preserves the heart in an ex vivo beating, perfused, normothermic and oxygenated state (Video 1). Although longer ischaemia times worsen prognosis [8], this device can contribute to consistent outcomes or to an expanded donor pool. The PROCEED-II trial (Randomized Study of Organ Care System Cardiac for Preservation of Donated Hearts for Eventual Transplantation), a randomized study, demonstrated non-inferiority in the OCS intention-to-treat group compared to standard cold-ischaemic preservation [58]. After receiving clinical approval due to the PROCEED-II trial’s findings, other investigators confirmed a favourable outcome in conjunction with OCS use in unfavourable donor–recipient constellations [59, 60]. Ex vivo preservation is also a significant chance in marginal organ selection to enable a post-mortem examination (e.g. using coronary angiography) and to evaluate metabolism, oxygen saturation, aortic pressure and coronary blood flow as surrogate parameters for good graft status. Furthermore, the application delivers valuable time for the transplant team to expand transport distances or use time for difficult situs preparation (e.g. explantation or preparation of MCS after several previous operations in adult patients with congenital heart defects). In addition, an economic benefit became apparent with a shorter period of ischaemia [61]."}

{"project":"TEST0","denotations":[{"id":"31106338-50-55-6312","span":{"begin":472,"end":473},"obj":"[\"28779893\"]"},{"id":"31106338-236-242-6313","span":{"begin":825,"end":827},"obj":"[\"25888086\"]"},{"id":"31106338-201-207-6314","span":{"begin":1031,"end":1033},"obj":"[\"25443013\"]"},{"id":"31106338-85-91-6315","span":{"begin":1682,"end":1684},"obj":"[\"20197346\"]"}],"text":"Facing increasing donor ages, all means must be undertaken to assess donated hearts as thoroughly as possible. New preservation technology [Organ Care System® (OCS), TransMedics, Andover, MA, USA] has been introduced to reduce ischaemic damage to the graft and enable further examination. This commercially available device preserves the heart in an ex vivo beating, perfused, normothermic and oxygenated state (Video 1). Although longer ischaemia times worsen prognosis [8], this device can contribute to consistent outcomes or to an expanded donor pool. The PROCEED-II trial (Randomized Study of Organ Care System Cardiac for Preservation of Donated Hearts for Eventual Transplantation), a randomized study, demonstrated non-inferiority in the OCS intention-to-treat group compared to standard cold-ischaemic preservation [58]. After receiving clinical approval due to the PROCEED-II trial’s findings, other investigators confirmed a favourable outcome in conjunction with OCS use in unfavourable donor–recipient constellations [59, 60]. Ex vivo preservation is also a significant chance in marginal organ selection to enable a post-mortem examination (e.g. using coronary angiography) and to evaluate metabolism, oxygen saturation, aortic pressure and coronary blood flow as surrogate parameters for good graft status. Furthermore, the application delivers valuable time for the transplant team to expand transport distances or use time for difficult situs preparation (e.g. explantation or preparation of MCS after several previous operations in adult patients with congenital heart defects). In addition, an economic benefit became apparent with a shorter period of ischaemia [61]."}

{"project":"2_test","denotations":[{"id":"31106338-28779893-28904625","span":{"begin":472,"end":473},"obj":"28779893"},{"id":"31106338-25888086-28904626","span":{"begin":825,"end":827},"obj":"25888086"},{"id":"31106338-25443013-28904627","span":{"begin":1031,"end":1033},"obj":"25443013"},{"id":"31106338-20197346-28904628","span":{"begin":1682,"end":1684},"obj":"20197346"}],"text":"Facing increasing donor ages, all means must be undertaken to assess donated hearts as thoroughly as possible. New preservation technology [Organ Care System® (OCS), TransMedics, Andover, MA, USA] has been introduced to reduce ischaemic damage to the graft and enable further examination. This commercially available device preserves the heart in an ex vivo beating, perfused, normothermic and oxygenated state (Video 1). Although longer ischaemia times worsen prognosis [8], this device can contribute to consistent outcomes or to an expanded donor pool. The PROCEED-II trial (Randomized Study of Organ Care System Cardiac for Preservation of Donated Hearts for Eventual Transplantation), a randomized study, demonstrated non-inferiority in the OCS intention-to-treat group compared to standard cold-ischaemic preservation [58]. After receiving clinical approval due to the PROCEED-II trial’s findings, other investigators confirmed a favourable outcome in conjunction with OCS use in unfavourable donor–recipient constellations [59, 60]. Ex vivo preservation is also a significant chance in marginal organ selection to enable a post-mortem examination (e.g. using coronary angiography) and to evaluate metabolism, oxygen saturation, aortic pressure and coronary blood flow as surrogate parameters for good graft status. Furthermore, the application delivers valuable time for the transplant team to expand transport distances or use time for difficult situs preparation (e.g. explantation or preparation of MCS after several previous operations in adult patients with congenital heart defects). In addition, an economic benefit became apparent with a shorter period of ischaemia [61]."}

{"project":"MyTest","denotations":[{"id":"31106338-28779893-28904625","span":{"begin":472,"end":473},"obj":"28779893"},{"id":"31106338-25888086-28904626","span":{"begin":825,"end":827},"obj":"25888086"},{"id":"31106338-25443013-28904627","span":{"begin":1031,"end":1033},"obj":"25443013"},{"id":"31106338-20197346-28904628","span":{"begin":1682,"end":1684},"obj":"20197346"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Facing increasing donor ages, all means must be undertaken to assess donated hearts as thoroughly as possible. New preservation technology [Organ Care System® (OCS), TransMedics, Andover, MA, USA] has been introduced to reduce ischaemic damage to the graft and enable further examination. This commercially available device preserves the heart in an ex vivo beating, perfused, normothermic and oxygenated state (Video 1). Although longer ischaemia times worsen prognosis [8], this device can contribute to consistent outcomes or to an expanded donor pool. The PROCEED-II trial (Randomized Study of Organ Care System Cardiac for Preservation of Donated Hearts for Eventual Transplantation), a randomized study, demonstrated non-inferiority in the OCS intention-to-treat group compared to standard cold-ischaemic preservation [58]. After receiving clinical approval due to the PROCEED-II trial’s findings, other investigators confirmed a favourable outcome in conjunction with OCS use in unfavourable donor–recipient constellations [59, 60]. Ex vivo preservation is also a significant chance in marginal organ selection to enable a post-mortem examination (e.g. using coronary angiography) and to evaluate metabolism, oxygen saturation, aortic pressure and coronary blood flow as surrogate parameters for good graft status. Furthermore, the application delivers valuable time for the transplant team to expand transport distances or use time for difficult situs preparation (e.g. explantation or preparation of MCS after several previous operations in adult patients with congenital heart defects). In addition, an economic benefit became apparent with a shorter period of ischaemia [61]."}

{"project":"testtesttest","denotations":[{"id":"T478","span":{"begin":140,"end":145},"obj":"Body_part"},{"id":"T480","span":{"begin":151,"end":157},"obj":"Body_part"},{"id":"T481","span":{"begin":338,"end":343},"obj":"Body_part"},{"id":"T485","span":{"begin":598,"end":603},"obj":"Body_part"},{"id":"T487","span":{"begin":609,"end":615},"obj":"Body_part"},{"id":"T488","span":{"begin":1102,"end":1107},"obj":"Body_part"},{"id":"T490","span":{"begin":1264,"end":1269},"obj":"Body_part"},{"id":"T491","span":{"begin":1581,"end":1586},"obj":"Body_part"}],"attributes":[{"id":"A478","pred":"uberon_id","subj":"T478","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"},{"id":"A479","pred":"uberon_id","subj":"T478","obj":"http://purl.obolibrary.org/obo/UBERON_0003103"},{"id":"A480","pred":"uberon_id","subj":"T480","obj":"http://purl.obolibrary.org/obo/UBERON_0000467"},{"id":"A481","pred":"uberon_id","subj":"T481","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"A482","pred":"uberon_id","subj":"T481","obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"A483","pred":"uberon_id","subj":"T481","obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"A484","pred":"uberon_id","subj":"T481","obj":"http://purl.obolibrary.org/obo/UBERON_0015230"},{"id":"A485","pred":"uberon_id","subj":"T485","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"},{"id":"A486","pred":"uberon_id","subj":"T485","obj":"http://purl.obolibrary.org/obo/UBERON_0003103"},{"id":"A487","pred":"uberon_id","subj":"T487","obj":"http://purl.obolibrary.org/obo/UBERON_0000467"},{"id":"A488","pred":"uberon_id","subj":"T488","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"},{"id":"A489","pred":"uberon_id","subj":"T488","obj":"http://purl.obolibrary.org/obo/UBERON_0003103"},{"id":"A490","pred":"uberon_id","subj":"T490","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A491","pred":"uberon_id","subj":"T491","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"A492","pred":"uberon_id","subj":"T491","obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"A493","pred":"uberon_id","subj":"T491","obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"A494","pred":"uberon_id","subj":"T491","obj":"http://purl.obolibrary.org/obo/UBERON_0015230"}],"text":"Facing increasing donor ages, all means must be undertaken to assess donated hearts as thoroughly as possible. New preservation technology [Organ Care System® (OCS), TransMedics, Andover, MA, USA] has been introduced to reduce ischaemic damage to the graft and enable further examination. This commercially available device preserves the heart in an ex vivo beating, perfused, normothermic and oxygenated state (Video 1). Although longer ischaemia times worsen prognosis [8], this device can contribute to consistent outcomes or to an expanded donor pool. The PROCEED-II trial (Randomized Study of Organ Care System Cardiac for Preservation of Donated Hearts for Eventual Transplantation), a randomized study, demonstrated non-inferiority in the OCS intention-to-treat group compared to standard cold-ischaemic preservation [58]. After receiving clinical approval due to the PROCEED-II trial’s findings, other investigators confirmed a favourable outcome in conjunction with OCS use in unfavourable donor–recipient constellations [59, 60]. Ex vivo preservation is also a significant chance in marginal organ selection to enable a post-mortem examination (e.g. using coronary angiography) and to evaluate metabolism, oxygen saturation, aortic pressure and coronary blood flow as surrogate parameters for good graft status. Furthermore, the application delivers valuable time for the transplant team to expand transport distances or use time for difficult situs preparation (e.g. explantation or preparation of MCS after several previous operations in adult patients with congenital heart defects). In addition, an economic benefit became apparent with a shorter period of ischaemia [61]."}